12:51 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Preclinical News

Fate's CAR Ts show efficacy

Fate Therapeutics Inc. (NASDAQ:FATE) presented data Monday at the American Association for Cancer Research meeting in Chicago showing that its off-the-shelf CAR T cell therapy FT819 elicited an immune response in cell studies.

FT819 cells are developed from an induced pluripotent stem cell (iPS cell) line and are engineered to lack a T...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >